Publication details
DLOUHODOBĚ PŮSOBÍCÍ INJEKČNÍ ANTIPSYCHOTIKA Z POHLEDU ÚHRAD A PODMÍNEK PRESKRIPCE U PACIENTŮ V AMBULANTNÍ PÉČI
| Title in English | LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN THE CONTEXT OF REIMBURSEMENT AND PRESCRIPTION CONDITIONS IN OUTPATIENTS |
|---|---|
| Authors | |
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Česká a slovenská psychiatrie |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.cspsychiatr.cz/detail.php?stat=1450 |
| Keywords | long-acting injectable antipsychotics; nonadherence; reimbursement conditions; reimbursement system; schizophrenia; usual daily therapeutic dose |
| Description | Schizophrenia is a heterogeneous serious mental illness that is characterized by severe impairment of mental function. Antipsychotics are the basis of therapy. Their role in medication is currently irreplaceable because they are allowing long-term treatment of the symptoms of schizophrenia and prevention of hospitalization in the event of relapse. Lack of insight at diagnosis, cognitive impairment, or side effects of antipsychotics, along with other factors, lead to nonadherence of patients in treatment, which thus becomes a key problem in long-term maintenance therapy. Long-acting injectable antipsychotics have been developed to reduce the relapse of the disease in patients in whom adherence to the oral form of the prescribed drugs cannot be ensured. They are administered parenterally either to hospitalized patients or, in the case of stabilized patients in home care, directly in the outpatient clinic, so it makes it possible to monitor the patient´s current condition. The administration of long-acting injectable antipsychotics in the outpatient clinic is due to prescription conditions, which result from the decision of the regulatory authority, and should be followed from the date of listing in the List of Reimbursed Medicinal Products. The objective of this review article is to provide an overview of the currently valid reimbursement conditions and an overview of reimbursements for the usual daily therapeutic doses for this specific pharmaceutical form of psychotropic drugs, from which the reimbursement of a specific medicinal product is subsequently calculated. The overview is supplemented by an explanation of the principles of the reimbursement system in the Czech Republic. |